April 2018

Trending on OncLive

Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia

TTFields Add a New Dimension to the Changing Pancreatic Cancer Treatment Paradigm

Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA

Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC

ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer